Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Regulatory
Approvals worldwideDrug spendingDrug targets
Regulatory · NICE technology appraisal guidance · England

NICE technology appraisals

Every medicine and treatment NICE has appraised for the NHS in England since 2000: NICE's recommendation, when it was published, whether it still stands, and a link to the guidance and to the medicine's trials on this site.

Source: NICE technology appraisal guidance and NICE's appraisal recommendations data, shown with NICE's permission. Checked 3 Oct 2026
1,189Technology appraisals published
90%Of 897 current decided appraisals recommend for at least some patients
72Published in 2026 so far
976Linked to a medicine page here
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from NICE technology appraisal guidance · Last verified · Editorial standards

NICE has published 1,189 technology appraisals since 2000, and 1,062 of them are still current. Of the current appraisals where NICE reached a decision, 90% recommend the medicine or treatment for at least some patients, including through the Cancer Drugs Fund. The most recent is TA1189, published 26 Aug 2026. NICE's decisions apply to the NHS in England; in Ireland the HSE decides on reimbursement, advised by the National Centre for Pharmacoeconomics.

01

What NICE decided

Appraisals by recommendation type
Recommended or optimised
836
Cancer Drugs Fund or Innovative Medicines Fund
64
Only in research
23
Not recommended
145
Terminated (no company submission)
177

An appraisal can contain several recommendations, for different groups of patients, so it can appear under more than one type. These explanations are ours; NICE's own definitions are on nice.org.uk.

02

All appraisals

1,189 appraisals, newest first, page 12 of 12
AppraisalMedicine pageNICE recommendationPublishedStatus
The use of autologous chondrocyte implantation for the treatment of cartilage defects in the knee joints
NICE TA89
—Only in research25 May 2005Replaced by TA477
Dual‑chamber pacemakers for symptomatic bradycardia due to sick sinus syndrome and/or atrioventricular block
NICE TA88
—Recommended23 Feb 2005
Updated 1 Nov 2014
Current
The clinical effectiveness and cost effectiveness of technologies for the secondary prevention of osteoporotic fractures in postmenopausal women
NICE TA87
Alendronate, Etidronate, TeriparatideOptimised26 Jan 2005Current
Imatinib for the treatment of unresectable and/or metastatic gastro-intestinal stromal tumours
NICE TA86
ImatinibRecommended27 Oct 2004
Updated 1 Nov 2010
Current
Immunosuppressive therapy for renal transplantation in adults
NICE TA85
Mycophenolate Mofetil, Sirolimus, TacrolimusRecommended Optimised22 Sep 2004Replaced by TA481
Drotrecogin alfa (activated) for severe sepsis
NICE TA84
—Recommended22 Sep 2004Current
Laparoscopic surgery for inguinal hernia repair
NICE TA83
—Recommended22 Sep 2004Current
Tacrolimus and pimecrolimus for atopic eczema
NICE TA82
Pimecrolimus, TacrolimusRecommended25 Aug 2004Current
Frequency of application of topical corticosteroids for atopic eczema
NICE TA81
Clobetasol Propionate, Fluticasone propionate, Hydrocortisone, Mometasone furoateRecommended25 Aug 2004Current
Clopidogrel in the treatment of non-ST-segment-elevation acute coronary syndrome
NICE TA80
ClopidogrelOptimised28 Jul 2004Replaced
Newer drugs for epilepsy in children
NICE TA79
Gabapentin, Lamotrigine, TopiramateRecommended28 Apr 2004Current
Fluid-filled thermal balloon and microwave endometrial ablation techniques for heavy menstrual bleeding
NICE TA78
—Recommended28 Apr 2004Current
Guidance on the use of zaleplon, zolpidem and zopiclone for the short-term management of insomnia
NICE TA77
—Recommended28 Apr 2004Current
Newer drugs for epilepsy in adults
NICE TA76
Gabapentin, Lamotrigine, Levetiracetam, TopiramateRecommended24 Mar 2004Current
Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C
NICE TA75
—Recommended28 Jan 2004
Updated 27 Nov 2013
Current
Pre-hospital initiation of fluid replacement therapy in trauma
NICE TA74
—Recommended28 Jan 2004Current
Myocardial perfusion scintigraphy for the diagnosis and management of angina and myocardial infarction
NICE TA73
—Recommended26 Nov 2003
Updated 1 Jul 2011
Current
The clinical effectiveness and cost effectiveness of anakinra for rheumatoid arthritis
NICE TA72
AnakinraOnly in research26 Nov 2003Current
Guidance on the use of coronary artery stents
NICE TA71
—Recommended Optimised22 Oct 2003
Updated 18 Nov 2020
Current
Guidance on the use of imatinib for chronic myeloid leukaemia
NICE TA70
ImatinibRecommended22 Oct 2003
Updated 21 Jan 2016
Current
Guidance on the use of liquid-based cytology for cervical screening
NICE TA69
—Recommended22 Oct 2003Current
Guidance on the use of photodynamic therapy for age-related macular degeneration
NICE TA68
—Optimised24 Sep 2003Current
The clinical effectiveness and cost effectiveness of amantadine and oseltamivir for the prophylaxis of influenza
NICE TA67
Amantadine, OseltamivirNot recommended Recommended24 Sep 2003Current
The clinical effectiveness and cost effectiveness of new drugs for bipolar disorder
NICE TA66
OlanzapineRecommended24 Sep 2003Current
Rituximab for aggressive non-Hodgkin's lymphoma
NICE TA65
RituximabRecommended Only in research24 Sep 2003Current
Human growth hormone (somatropin) in adults with growth hormone deficiency
NICE TA64
SomatropinOptimised27 Aug 2003Current
Glitazones in the treatment of type 2 diabetes
NICE TA63
PioglitazoneOptimised27 Aug 2003Current
Guidance on the use of capecitabine for the treatment of locally advanced or metastatic breast cancer
NICE TA62
CapecitabineRecommended28 May 2003Current
Guidance on the use of capecitabine and tegafur with uracil for metastatic colorectal cancer
NICE TA61
Capecitabine, TegafurRecommended27 May 2003Current
Guidance on the use of patient-education models for diabetes
NICE TA60
—Recommended26 Apr 2003
Updated 1 Aug 2015
Replaced
Guidance on the use of electroconvulsive therapy
NICE TA59
—Optimised26 Apr 2003
Updated 1 Oct 2009
Current
Flu treatment - zanamivir, amantadine and oseltamivir
NICE TA58
Amantadine, OseltamivirNot recommended Recommended26 Feb 2003Current
The clinical effectiveness and cost effectiveness of insulin pump therapy
NICE TA57
—Optimised Not recommended26 Feb 2003Current
The clinical effectiveness and cost effectiveness of tension-free vaginal tape for stress incontinence
NICE TA56
—Recommended26 Feb 2003Current
Guidance on the use of paclitaxel in the treatment of ovarian cancer
NICE TA55
PaclitaxelRecommended22 Jan 2003
Updated 1 May 2005
Current
Guidance on the use of vinorelbine for the treatment of advanced breast cancer
NICE TA54
VinorelbineNot recommended Recommended13 Dec 2002Current
Guidance on the use of long‑acting insulin analogues for the treatment of diabetes – insulin glargine
NICE TA53
Insulin glargineRecommended Optimised6 Dec 2002
Updated 1 Aug 2015
Replaced
Guidance on the use of drugs for early thrombolysis in the treatment of acute myocardial infarction
NICE TA52
Alteplase, TenecteplaseRecommended30 Oct 2002Current
Computerised cognitive behaviour therapy (CCBT) for the treatment of depression and anxiety
NICE TA51
—Only in research24 Oct 2002Replaced by TA97
Imanitib for chronic myeloid leukaemia
NICE TA50
ImatinibRecommended16 Oct 2002Replaced by TA70
Guidance on the use of ultrasound locating devices for placing central venous catheters
NICE TA49
—Not recommended Optimised4 Oct 2002Current
Guidance on home compared with hospital haemodialysis for patients with end-stage renal failure
NICE TA48
—Recommended26 Sep 2002Current
Guidance on the use of glycoprotein IIb/IIIa inhibitors in the treatment of acute coronary syndromes
NICE TA47
TirofibanRecommended5 Sep 2002
Updated 1 Mar 2010
Current
The clinical effectiveness and cost effectiveness of surgery for people with morbid obesity
NICE TA46
—Recommended19 Jul 2002Current
Ovarian cancer (advanced) - paclitaxel, pegylated liposomal doxorubicin hydrochloride and topotecan
NICE TA45
Pegylated liposomal doxorubicinRecommended19 Jul 2002Current
Guidance on the use of metal on metal hip resurfacing arthroplasty
NICE TA44
—Only in research26 Jun 2002Replaced by TA304
The clinical effectiveness and cost effectiveness of newer atypical antipsychotic drugs for schizophrenia
NICE TA43
Olanzapine, Quetiapine, RisperidoneRecommended26 Jun 2002Current
Human growth hormone for the treatment growth failure in children
NICE TA42
SomatropinRecommended27 May 2002Current
The clinical effectiveness and cost effectiveness of routine anti-D prophylaxis for RhD-negative women in pregnancy
NICE TA41
—Recommended27 May 2002Replaced by TA156
The clinical effectiveness and cost effectiveness of infliximab for Crohn's disease
NICE TA40
InfliximabRecommended26 Apr 2002Current
The clinical effectiveness and cost effectiveness of bupropion (Zyban) and Nicotine Replacement Therapy for smoking cessation
NICE TA39
Nicotine replacement, BupropionRecommended27 Mar 2002Current
Inhaler devices for routine treatment of chronic asthma in older children (aged 5 to 15 years)
NICE TA38
—Recommended27 Mar 2002Current
The clinical effectiveness and cost effectiveness of rituximab for follicular lymphoma
NICE TA37
RituximabOnly in research Not recommended27 Mar 2002Current
The clinical effectiveness and cost effectiveness of etanercept and infliximab for rheumatoid arthritis and juvenile poly-articular idiopathic arthritis
NICE TA36
EtanerceptOptimised27 Mar 2002Replaced by TA130
Guidance on the use of etanercept for the treatment of juvenile idiopathic arthritis
NICE TA35
EtanerceptRecommended27 Mar 2002Current
Guidance on the use of trastuzumab for the treatment of advanced breast cancer
NICE TA34
TrastuzumabRecommended15 Mar 2002Current
The clinical effectiveness and cost effectiveness of irinotecan, oxaliplatin and raltitrexed for colorectal cancer
NICE TA33
Irinotecan, Oxaliplatin, RaltitrexedNot recommended Recommended Optimised Only in research27 Mar 2002Replaced by TA93
Beta interferon and glatiramer acetate for the treatment of multiple sclerosis
NICE TA32
—Not recommended23 Jan 2002Current
The clinical effectiveness and cost effectiveness of sibutramine for obesity
NICE TA31
—Recommended28 Oct 2001Replaced
Taxanes for the treatment of breast cancer
NICE TA30
Docetaxel, PaclitaxelNot recommended Recommended26 Sep 2001Replaced
Guidance on the use of fludarabine for B-cell chronic lymphocytic leukaemia
NICE TA29
FludarabineRecommended26 Sep 2001Current
Ovarian cancer - topotecan
NICE TA28
TopotecanRecommended23 Jul 2001Replaced by TA91
Cox-II inhibitors for the treatment of osteoarthritis and rheumatoid arthritis
NICE TA27
CelecoxibOptimised23 Jul 2001Replaced
Docetaxel, paclitaxel, gemcitabine and vinorelbine for the treatment of non-small cell lung cancer
NICE TA26
Docetaxel, Gemcitabine, Paclitaxel, VinorelbineRecommended26 Jun 2001Replaced
Guidance on the use of gemcitabine for the treatment of pancreatic cancer
NICE TA25
GemcitabineRecommended Not recommended8 May 2001Replaced
Wound care - debriding agents
NICE TA24
—Recommended27 Apr 2001Replaced
Guidance on the use of temozolomide for the treatment of recurrent malignant glioma (brain cancer)
NICE TA23
TemozolomideRecommended26 Apr 2001
Updated 3 Mar 2016
Current
Orlistat for the treatment of obesity in adults
NICE TA22
OrlistatRecommended27 Mar 2001Replaced
Diabetes (type 2) - pioglitazone
NICE TA21
PioglitazoneRecommended27 Mar 2001Replaced by TA63
Guidance on the use of riluzole (Rilutek) for the treatment of motor neurone disease
NICE TA20
RiluzoleRecommended23 Jan 2001Current
Alzheimer's disease (mild to moderate) - donepezil, rivastigmine and galantamine
NICE TA19
Donepezil, GalantamineOptimised23 Jan 2001Replaced by TA111
Laparoscopic surgery for hernia
NICE TA18
—Recommended23 Jan 2001Replaced by TA83
Laparoscopic surgery for colorectal cancer
NICE TA17
—Only in research16 Dec 2000Replaced by TA105
Autologous cartilage transplantation for full thickness cartilage defects in knee joints
NICE TA16
—Only in research16 Dec 2000Replaced by TA89
Zanamivir for the treatment of influenza in adults
NICE TA15
—Recommended27 Nov 2000Replaced by TA58
The clinical and cost effectiveness of pegylated interferon alpha 2a and alpha 2b for hepatitis C
NICE TA14
—Recommended28 Oct 2000Replaced by TA75
Methylphenidate for the treatment of attention deficit hyperactivity disorder in children and adolescents
NICE TA13
MethylphenidateRecommended28 Oct 2000Replaced
Glycoprotein IIb/IIIa inhibitors in the treatment of acute coronary syndromes
NICE TA12
TirofibanRecommended26 Sep 2000Replaced by TA47
Implantable cardioverter defibrillators (ICDs) for the treatment of arrhythmias
NICE TA11
—Recommended26 Sep 2000Replaced by TA95
Guidance on the use of inhaler systems (devices) in children under the age of 5 years with chronic asthma
NICE TA10
—Recommended23 Aug 2000Current
Diabetes (type 2) - rosiglitazone
NICE TA9
—Recommended23 Aug 2000Replaced by TA63
Hearing disability - hearing aids
NICE TA8
—Not recommended Recommended23 Jul 2000Withdrawn
The clinical and cost effectiveness of proton pump inhibitors for the treatment of dyspepsia
NICE TA7
Lansoprazole, Omeprazole, Pantoprazole, RabeprazoleRecommended23 Jul 2000Replaced
Taxanes for the treatment of breast cancer
NICE TA6
Docetaxel, PaclitaxelRecommended26 Jun 2000Replaced by TA30
Liquid-based cytology for cervical screening
NICE TA5
—Only in research26 Jun 2000Replaced by TA69
Ischaemic heart disease - coronary artery stents
NICE TA4
—Recommended27 May 2000Replaced by TA71
Ovarian cancer - taxanes
NICE TA3
PaclitaxelRecommended27 May 2000Replaced by TA55
Guidance on the Selection of Prostheses for Primary Total Hip Replacement
NICE TA2
—Recommended26 Apr 2000Replaced by TA304
Guidance on the extraction of wisdom teeth
NICE TA1
—Recommended27 Mar 2000Current

Titles link to the guidance on nice.org.uk, where the full recommendations are. A medicine is linked to its page here only when the name NICE appraised is exactly the same molecule as ours; medicines given alongside it (“with chemotherapy”) are not counted as appraised. Appraisals of devices and procedures are listed but have no medicine page.

© NICE 2026 technology appraisal guidance. Available from www.nice.org.uk/guidance. All rights reserved. Subject to Notice of rights. NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.

Medicines data, weekly

One email every Friday: new approvals, trials and shortages, with every figure linked to its source.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

NICE has allowed us to show the appraisal number, title, recommendation category and dates of each technology appraisal, with a link to the guidance. No guidance text is reproduced.

A nightly job reads NICE's recommendations data, reads each new appraisal page once and re-checks every page every 60 days for replaced or withdrawn guidance. It keeps the previous version if a refresh fails. No AI drafting. See our methodology. The NICE data on this page was last retrieved on 3 Oct 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.